Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-716
- Sponsors Merck Sharp & Dohme
- 12 Sep 2018 Status changed from not yet recruiting to recruiting.
- 30 Aug 2018 Planned initiation date changed from 28 Sep 2018 to 14 Sep 2018.
- 19 Jun 2018 New trial record